| Literature DB >> 32640531 |
Antonio J Martínez-Ortega1,2, Gabriel Olveira3,4,5, José L Pereira-Cunill1,2, Carmen Arraiza-Irigoyen6, José M García-Almeida4,7, José A Irles Rocamora8, María J Molina-Puerta9,10, Juan B Molina Soria11, Juana M Rabat-Restrepo12, María I Rebollo-Pérez13, María P Serrano-Aguayo1,2, Carmen Tenorio-Jiménez14, Francisco J Vílches-López15, Pedro P García-Luna1,2,16.
Abstract
In order to develop evidence-based recommendations and expert consensus for nutrition management of patients undergoing bariatric surgery and postoperative follow-up, we conducted a systematic literature search using PRISMA methodology plus critical appraisal following the SIGN and AGREE-II procedures. The results were discussed among all members of the GARIN group, and all members answered a Likert scale questionnaire to assess the degree of support for every recommendation. Patients undergoing bariatric surgery should be screened preoperatively for some micronutrient deficiencies and treated accordingly. A VLCD (Very Low-Calorie Diet) should be used for 4-8 weeks prior to surgery. Postoperatively, a liquid diet should be maintained for a month, followed by a semi-solid diet also for one month. Protein requirements (1-1.5 g/kg) should be estimated using adjusted weight. Systematic use of specific multivitamin supplements is encouraged. Calcium citrate and vitamin D supplements should be used at higher doses than are currently recommended. The use of proton-pump inhibitors should be individualised, and vitamin B12 and iron should be supplemented in case of deficit. All patients, especially pregnant women, teenagers, and elderly patients require a multidisciplinary approach and specialised follow-up. These recommendations and suggestions regarding nutrition management when undergoing bariatric surgery and postoperative follow-up have direct clinical applicability.Entities:
Keywords: Bariatric surgery; nutrient deficiency; obesity
Mesh:
Year: 2020 PMID: 32640531 PMCID: PMC7400832 DOI: 10.3390/nu12072002
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram following the PRISMA methodology that reflects the selection and evaluation process of the analysed papers.
Level of Evidence (LoE) assigned to each article according to its quality.
| LoE | Interpretation |
|---|---|
| 1++ | High quality meta-analyses, systematic reviews of CTs, or high quality CTs with a very low risk of bias |
| 1+ | Well conducted meta-analyses, systematic reviews of CTs, or well conducted CTs with a low risk of bias |
| 1− | Meta-analyses, systematic reviews of CTs, or CTs with a high risk of bias |
| 2++ | High quality systematic reviews of case control or cohort studies. Case control or cohort studies with a low risk of bias and a high probability that the relationship is causal |
| 2+ | Well conducted case control or cohort studies with a low risk of bias and a moderate probability that the relationship is causal |
| 2− | Case control or cohort studies with a high risk of bias and a significant risk that the relationship is not causal |
| 3 | Non-analytic studies, e.g., case reports and case series |
| 4 | Expert opinion |
Abbreviations: CTs: Controlled Clinical Trials.
Degree of recommendation applicable to each consensus response according to the supporting evidence.
| Grade of Recommendation | Interpretation |
|---|---|
| A | At least one meta-analysis, systematic review, or CT rated as 1++, and directly applicable to the guidelines target population; or A body of scientific evidence consisting of studies rated as 1+ and demonstrating overall consistency of results. |
| B | A body of scientific evidence including studies rated as 2++, directly applicable to the guidelines target population, and demonstrating overall consistency of results; or Extrapolated scientific evidence from studies rated as 1++ or 1+ |
| C | A body of scientific evidence including studies rated as 2+, directly applicable to the guidelines target population and demonstrating overall consistency of results; or Extrapolated scientific evidence from studies rated as 2++ |
| D | Scientific evidence level 3 or 4; or Extrapolated scientific evidence from studies rated as 2+ |
List of study articles/guidelines used to respond to the 20 selected questions.
| Articles Used to Answer Each Question | ||||
|---|---|---|---|---|
| First Author | Type of Study | SIGN/AGREE II Score | LoE | Reference |
| Aaseth E | Case series | No checklist required | 3 | [ |
| Abdemur A | Case series | No checklist required | 3 | [ |
| Adams TD | Case-control study | High quality (++) | 2++ | [ |
| Alexandrou A | Transversal study | No checklist required | 3 | [ |
| Aron-Wisnewsky J | Case series | No checklist required | 3 | [ |
| Bailly L | Case series | No checklist required | 3 | [ |
| Basfi-Fer K | Case series | No checklist required | 3 | [ |
| Ben-Porat T | Case series | No checklist required | 3 | [ |
| Benassar Remolar MA | Case series | No checklist required | 3 | [ |
| Botella-Carretero JI | Case series | No checklist required | 3 | [ |
| Botella Romero F | Case series | No checklist required | 3 | [ |
| Boyce SG | Case series | No checklist required | 3 | [ |
| Brethauer SA | Systematic review | Low quality (−) | 1− | [ |
| Busetto L | Practice guideline | 74.53% Good quality | NA | [ |
| Cabral J | Systematic review | Low quality (−) | 1− | [ |
| Caron M | Case series | No checklist required | 3 | [ |
| Casillas RA | Case series | No checklist required | 3 | [ |
| Chagas C | Case series | No checklist required | 3 | [ |
| Chakhtoura MT | Systematic review | Acceptable (+) | 1+ | [ |
| Chakhtoura MT | Systematic review | High quality (++) | 1++ | [ |
| Chakhtoura MT | Systematic review | High quality (++) | 1++ | [ |
| Coblijn UK | Systematic review | Acceptable (+) | 1+ | [ |
| Coblijn UK | Systematic review | Low quality (−) | 1− | [ |
| Cosendey Menegati G | Case-control study | Acceptable (+) | 2+ | [ |
| Costa TL | Case-control study | Acceptable (+) | 2+ | [ |
| Dagan SS | Cohort study | Acceptable (+) | 2+ | [ |
| Daigle CR | Case series | No checklist required | 3 | [ |
| De Luis DA | Case series | No checklist required | 3 | [ |
| Del Villar Madrigal E | Case series | No checklist required | 3 | [ |
| Dogan K | Case series | No checklist required | 3 | [ |
| Dunstan M | Case series | No checklist required | 3 | [ |
| Edholm D | Case series | No checklist required | 3 | [ |
| Edholm D | Case series | No checklist required | 3 | [ |
| Elbahrawy A | Case series | No checklist required | 3 | [ |
| Elhag W | Case series | No checklist required | 3 | [ |
| Fashandi AZ | Case series | No checklist required | 3 | [ |
| Ferreira-Nicoletti C | Pre-post study | No checklist required | 3 | [ |
| Flores L | NRCT | Acceptable (+) | 1+ | [ |
| Flores L | Case series | No checklist required | 3 | [ |
| Froylich D | Case series | No checklist required | 3 | [ |
| Fulton C | Case series | No checklist required | 3 | [ |
| Gadgil MD | Case-control study | High quality (++) | 2++ | [ |
| Gebhart A | Case series | No checklist required | 3 | [ |
| Gesquiere I | Case series | No checklist required | 3 | [ |
| Gesquiere I | Case series | No checklist required | 3 | [ |
| Gillon S | Case series | No checklist required | 3 | [ |
| Gimenes JC | Transversal study | No checklist required | 3 | [ |
| Gimenes JC | Case series | No checklist required | 3 | [ |
| Giordano S | Systematic review | High quality (++) | 1++ | [ |
| Giordano S | Systematic review | Acceptable (+) | 1+ | [ |
| Gobato RC | Case series | No checklist required | 3 | [ |
| Goldberg HR | Case series | No checklist required | 3 | [ |
| Gomes de Lima KV | Case series | No checklist required | 3 | [ |
| González-Navarro I | Case series | No checklist required | 3 | [ |
| Grace, C | Case series | No checklist required | 3 | [ |
| Gregory DM | Pre-post study | No checklist required | 3 | [ |
| Haywood C | Systematic review | Low quality (−) | 1− | [ |
| Homan J | Case series | No checklist required | 3 | [ |
| Hsin MC | Cohort study | Acceptable (+) | 2+ | [ |
| Iannelli A | Case series | No checklist required | 3 | [ |
| James H | Case series | No checklist required | 3 | [ |
| Jans G | Systematic review | Low quality (−) | 2++ | [ |
| Jans G | Cohort study | Acceptable (+) | 2+ | [ |
| Jáuregui-Lobera I | Systematic review | Acceptable (+) | 1+ | [ |
| Kalani A | Systematic review | High quality (++) | 1++ | [ |
| Kim MK | Case series | No checklist required | 3 | [ |
| Kiyomi-Ito M | Systematic review | High quality (++) | 1++ | [ |
| Kornerup LS | Case series | No checklist required | 3 | [ |
| Kwon Y | Systematic review | High quality (++) | 1++ | [ |
| Krzizek EC | Case series | No checklist required | 3 | [ |
| Lecube A | Transversal study | No checklist required | 3 | [ |
| Lefebvre P | Case series | No checklist required | 3 | [ |
| Leite Faria, S | Open RCT | Acceptable (+) | 1− | [ |
| Li Z | Systematic review | High quality (++) | 1++ | [ |
| Liu C | Systematic review | High quality (++) | 1++ | [ |
| Lucas Soares F | Case series | No checklist required | 3 | [ |
| Luger M | RCT | High quality (++) | 1+ | [ |
| Majumder S | Systematic review | Low quality (−) | 1− | [ |
| Malone M | Case series | No checklist required | 3 | [ |
| Mann JP | Systematic review | Low quality (−) | 1− | [ |
| Manousou S | Case-control study | High quality (++) | 2++ | [ |
| Marczuk P | Systematic review | High quality (++) | 1++ | [ |
| Martín García-Almenta E | Practice guideline | 54.03% Low quality | NA | [ |
| McCracken E | Case-control study | High quality (++) | 2++ | [ |
| McGlone ES | Case series | No checklist required | 3 | [ |
| Mead NC | Transversal study | No checklist required | 3 | [ |
| Mechanick JL | Practice guideline | 90.06% Excellent quality | NA | [ |
| Mendes-Filho AM | Systematic review | Low quality (−) | 1− | [ |
| Mingrone G | Systematic review | Low quality (−) | 1− | [ |
| Mischler R | RCT | Low quality (−) | 1− | [ |
| Mischler R | Transversal study | No checklist required | 3 | [ |
| Moizé V | Case series | No checklist required | 3 | [ |
| Moore CE | Case series | No checklist required | 3 | [ |
| Morales MP | Case series | No checklist required | 3 | [ |
| Nicoletti CF | Case series | No checklist required | 3 | [ |
| O’Kane M | Practice guideline | 77.63% Good quality | NA | [ |
| Obeid NR | Case series | No checklist required | 3 | [ |
| Obinwanne K | Case series | No checklist required | 3 | [ |
| Obinwanne K | Case series | No checklist required | 3 | [ |
| Olbers T | Cohort study | High quality (++) | 2+ | [ |
| Parmar C | Transversal study | No checklist required | 3 | [ |
| Parrot J | Practice guideline | 63.35% Acceptable quality | NA | [ |
| Pędziwiatr M | Systematic review | High quality (++) | 1++ | [ |
| Pellitero S | Case series | No checklist required | 3 | [ |
| Pereira S | NRCT | Acceptable (+) | 1− | [ |
| Pereira Da Cruz S | Cohort study | High quality (++) | 2+ | [ |
| Pereira-Santos M | Systematic review | High quality (++) | 1++ | [ |
| Pérez Quirante F | Transversal study | No checklist required | 3 | [ |
| Peterson LA | Systematic review | Low quality (−) | 1− | [ |
| Peterson LA | Transversal study | No checklist required | 3 | [ |
| Pinto-Bastos A | Systematic review | Low quality (−) | 1− | [ |
| Pratt JSA | Practice guideline | 70.8% Good quality | NA | [ |
| Quezada N | Case series | No checklist required | 3 | [ |
| Rodríguez-Carmona Y | Systematic review | High quality (++) | 1++ | [ |
| Rottenstreich A | Case series | No checklist required | 3 | [ |
| Rousseau C | Case-control study | High quality (++) | 2++ | [ |
| Ruíz-Tovar J | Case series | No checklist required | 3 | [ |
| Sakhaee K | RCT | Acceptable (+) | 1+ | [ |
| Sakhaee K | RCT | Acceptable (+) | 1+ | [ |
| Salgado W | Case series | No checklist required | 3 | [ |
| Sallé A | Case series | No checklist required | 3 | [ |
| Sánchez A | Transversal study | No checklist required | 3 | [ |
| Santarpia, L | Case series | No checklist required | 3 | [ |
| Schiavo L | Pre-post study | No checklist required | 3 | [ |
| Schijns W | Cohort study | Acceptable (+) | 2+ | [ |
| Schneider J | RCT | Acceptable (+) | 1+ | [ |
| Schollenberger AE | RCT | Acceptable (+) | 1+ | [ |
| Shah M | Case series | No checklist required | 3 | [ |
| Sheng B | Systematic review | High quality (++) | 1+ | [ |
| Sherf-Dagan S | Transversal study | No checklist required | 3 | [ |
| Sjöström L | Cohort study | Acceptable (+) | 2+ | [ |
| Souza Silva J | Pre-post study | No checklist required | 3 | [ |
| Susmallian S | Case series | No checklist required | 3 | [ |
| Susmallian S | Case series | No checklist required | 3 | [ |
| Tang L | Case series | No checklist required | 3 | [ |
| Tondapu P | RCT | Acceptable (+) | 1+ | [ |
| Topart P | Case series | No checklist required | 3 | [ |
| Tran DD | Systematic review | Low quality (−) | 1− | [ |
| Upala S | Systematic review | High quality (++) | 1+ | [ |
| Van Nieuwenhove Y | RCT | Acceptable (+) | 1+ | [ |
| Van Rutte PWJ | Pre-post study | No checklist required | 3 | [ |
| Verger EO | Case series | No checklist required | 3 | [ |
| Vinan-Vega M | Case-control study | Acceptable (+) | 2+ | [ |
| Wang C | Case series | No checklist required | 3 | [ |
| Wang FG | Systematic review | High quality (++) | 1++ | [ |
| Ward EK | Retrospective cohort study | Acceptable (+) | 2+ | [ |
| Wolf E | Transversal study | No checklist required | 3 | [ |
| Wei JH | Pre-post study | No checklist required | 3 | [ |
| Wang TC | Systematic review | High quality (++) | 1++ | [ |
| White MG | Case series | No checklist required | 3 | [ |
| Wu Chao Ying V | Systematic review | High quality (++) | 1++ | [ |
| Yorke E | Case series | No checklist required | 3 | [ |
| Yska JP | Case series | No checklist required | 3 | [ |
| Zhang Q | Systematic review | High quality (++) | 1++ | [ |
Abbreviations: NA, Not Applicable; NRCT Non-Randomised Controlled Trial; RCT, Randomised Controlled Trial.
VLCD main characteristics.
| Total Caloric Value (Kcal/day) | 450–800 |
|---|---|
| Carbohydrate content | At least 55 gr/day |
| Protein content | 50 gr/day (high biological value) |
| Lipids | 7 gr |
| Linoleic acid | 3 gr |
| Alpha-linolenic acid | 0.5 gr |
| Fibre | 10 gr |
| Vitamins, micronutrients and trace elements | 100% of daily requirements |
Follow-up analytical recommendations.
| Pre-Surgery | 1 Month | 3 Months | 6 Months | 12 Months | Annual | |
|---|---|---|---|---|---|---|
| CBC/Biochemistry | X | X | X | X | X | X |
| Albumin | X | X | X | X | X | X |
| Prealbumin | X |
|
|
|
|
|
| CRP | X | X | X | X | X | X |
| Iron/Ferritin | X | X | X | X | X | |
| Ca/P/Mg | X | X | X | X | X | |
| iPTH | X | X | X | |||
| B12/Folic acid | X | X * | XA | XA | XA | |
| Vitamin D | X | X | X | X | ||
| Zn/Cu |
|
|
| |||
| B1 |
|
|
| |||
| Vitamin A and E | X | X A | X A |
* It is advisable to request in case of preoperative deficit. In other cases, optional. A Mandatory in malabsorptive surgery, optional in restrictive. X: must be done.
Comparison between the composition of different multivitamins available in Spain.
| Recommendations of the American Society for Metabolic and Bariatric Surgery (ASMBS) | Multicentrum (Per tablet) | Multi-Tenex (Per tablet) | Supradyn (Per tablet) | Micebrina Complex | |
|---|---|---|---|---|---|
| Vit A, μg | 1500–3000 | 800 | 800 | 800 | 450 |
| Vit B1, mg | 1.2 | 1.4 | 1.4 | 1.1 | 10 |
| Vit B12, μg | 350–500 | 2.5 | 1 | 2.5 | 12 |
| Vit D3, μg | 75 | 5 | 5 | 5 | 10 |
| Vit E, mg | 15 | 15 | 10 | 12 | 30 |
| Vit K, μg | 90–120 | 30 | - | 25 | - |
| Copper, mg | 1–2 | 0.5 | 2 | 1 | 2 |
| Iron, mg | 45–60 | 5 | 14 | 14 | 18 |
| Zinc, mg | 8–22 | 5 | 14 | 10 | 15 |
| Calcium, mg | 1200–1500 | 162 | 100 | 120 | 0.15 (Calcium iodate) |
Table prepared according to data provided by the manufacturer.
Final recommendations/suggestions reached in the present review.
| Recommendation | Grade of Recommendation/Consensus Level |
|---|---|
| It is convenient to determine the levels of certain micronutrients and vitamins preoperatively, at least vitamin D and iron metabolism. Folic acid and B12 vitamin should be included in certain populations | D/93% |
| Specific micronutrient supplements should be used if there is any evidence of any preoperative deficit following the current treatment recommendations | D/100% |
| We recommend the use of a liquid VLCD diet preoperatively, for at least 4-8 weeks minimum prior to surgery and ideally for a longer length of time in selected patients | B/91% |
| After surgery, a liquid diet should be maintained for about 4 weeks, and then a semi-solid diet for another 4 weeks | D/84% |
| The GARIN group advises against calculating the protein provision based on a percentage of the diet’s total caloric value, since this method often results in insufficient intake. Instead, it is advisable to use a direct calculation based on the adjusted weight, at least 1 to 1.5 gr of high biological value protein per Kg of weight and day | D/96% |
| The use of protein supplements could be beneficial in the 6-12 months after surgery | B/96% |
| The postoperative use of calcium (1000 mg of calcium element at least) and vitamin D (880 IU of cholecalciferol) supplements are recommended | A/91% |
| In biliopancreatic diversion/Scopinaro surgeries the GARIN group recommends a higher intake of calcium (2000 mg/d) and especially a higher intake of vitamin D (2000 IU/d) | D/91% |
| Periodic monitoring of iron levels after surgery should be performed, and in the case of deficit, treated accordingly | D/85% |
| Use of parenteral treatment for vitamin B12 deficiency only if the deficit is evident | D/85% |
| Although there is no scientific evidence, a consideration of the pathophysiological mechanism of Obesity Surgery, especially malabsorptive surgery, would make an increase of the dietary intake of other micronutrients, including supplements recommendable | D/89% |
| Calcium citrate preparations should be recommended above other calcium compounds, especially in RYGBP | B/93% |
| The GARIN group suggest periodic and customised analytical follow-up after surgery. Vitamin A, E, B12 and folic acid are mandatory in malabsorptive surgery (See text for details) | D/89% |
| The GARIN group recommends individualising the use and duration of PPI therapy | D/96% |
| We recommend the systematic use of multivitamin and mineral complexes | C/98% |
| The GARIN group recommends, whenever available, the use of supplements that are specifically designed for patients undergoing Obesity Surgery | D/85% |
| We recommend periodical kidney function monitoring using serum creatinine and specific formulas to estimate glomerular filtration, occasional 24-hourour urine calcium, and, in selected cases, imaging tests, at least in patients who underwent RYGBP to rule out kidney stones. | D/84% |
| After one year post-surgery, the GARIN group recommends annual check-ups in Specialised Care for at least five years of all patients who underwent Obesity Surgery. After this time, it is advisable to maintain annual check-ups in patients who underwent malabsorptive techniques, while those patients without complications who underwent purely restrictive techniques do not require specialised follow-up, except in selected cases | D/87% |
| The GARIN group recommends that in patients with T2DM, RYGBP should be considered before LSG; independently of the technique used, it should be performed by a Surgical Team with experience in that technique | D/91% |
| Pregnancy should be avoided in the first year after Obesity Surgery, and contraceptive measures should be routinely recommended | D/87% |
| All women of childbearing age undergoing Obesity Surgery should programme their gestation at an experienced centre | D/87% |
| Possible micronutrient deficits (Vitamin A, D, E, K, B12, folic, iron) should be detected (AND treated) at least every six months prior to gestation, in each trimester of pregnancy (or sooner if any type of deficit is detected ) and at 6-8 weeks post-partum, especially in case of breastfeeding. | C/87% |
| Breastfeeding is encouraged | D/87% |
| In selected adolescent population between 13 and 18 years LSG can be considered for weight loss | D/87% |
| In selected adolescent patients between 13 and 18 years, RYGBP can be considered for weight loss, especially in patients with prediabetes/T2DM, hypertension and/or dyslipidaemia | C/87% |
| BGYR should be discouraged in people over 65, especially in cases of high cardiovascular risk | A/87% |
| In selected patients over 65 years LSG could be considered as an option | B/87% |
| If re-intervention is needed due to poor results in weight loss, RYGBP after LSG is an effective and safe option, allowing additional weight loss and improvement of comorbidities. If the first surgery was RYGBP, biliopancreatic diversion seems to be the most favourable technique | B/75% |